


Synthesis and Chemical Reactivity of Tetrahydro[60]fullerene **Epoxides with Both Amino and Aryl Addends**

Sisi Liang,[†] Liang Xu,[†] and Liangbing Gan*,[†],[‡]

[†]Beijing National Laboratory for Molecular Sciences, Key Laboratory of Bioorganic Chemistry and Molecular Engineering of the Ministry of Education, College of Chemistry and Molecular Engineering, Peking University, Beijing 100871, China

Supporting Information

ABSTRACT: Tetrahydro [60] fullerene epoxides $C_{60}(O)$ - $Ar_n(NR_2)_{4-n}$, n = 1, 2, have been prepared by treating 1,4adducts $C_{60}(OH)$ Ph and $C_{60}(Tol)_2$ with cyclic secondary amines. The epoxy moieties in these mixed tetrahydro [60]fullerene epoxides were hydrolyzed into the corresponding diol derivatives, which were further oxidized into diketone open-cage fullerenes with a 10-membered orifice. A few other reactions also showed that the present tetrahydro [60] fullerene



epoxides with both amino and aryl addends exhibit improved chemical reactivity over the tetraamino [60] fullerene epoxide without any aryl group.

■ INTRODUCTION

The skew-pentagonal-pyramid addition products C_s - $C_{60}X_6$ and C_s-C₆₀YX₅ are among the extensively studied fullerene multiadducts. 1,2 They are formed through the cyclopentadienyl type addition pattern in which five addends are attached around the same pentagon and another addend on the pentagon. A closely related multiadduct is the tetrahydro[60]fullerene epoxide C_s - $C_{60}(O)X_4$. Compared to $C_{60}X_6$ and $C_{60}YX_5$, which have various different types of addends, the tetrahydro[60]fullerene epoxide is quite limited. The first such epoxide is a tetraamino C₆₀ epoxide from the reaction of secondary amine with C₆₀ in the presence of oxygen.³ Later, various other secondary amines have been shown to form this type of adducts with C₆₀ in good yields under different conditions.⁴ Hydrogen peroxides such as t-butylhydrogen peroxide can also react efficiently with C₆₀ to form the tetraperoxo epoxy adduct.⁵ Even though many different aryl groups can form the pentaaryl adduct C₆₀Ar₅H, ^{1c,6} only the triphenylamine derived adduct can be converted to the epoxide $C_{60}(O)Ar_4$ by deprotonation induced dearylation in the presence of oxygen.⁷ Remarkably, the tetraperfluoroalkyl C_{60} epoxides $C_{60}(O)(CF_3)_4$ and $C_{60}(O)(C_2F_5)_4$ were isolated in low yields from the complex reaction mixture between C₆₀ and CF₃I or C₂F₅I, respectively, at high temperature. 8 Biological activities of the tetraamino C_{60} epoxides have been explored, but further reaction study of the tetrahydro [60] fullerene epoxides is mainly limited to the peroxo adduct. 10 Here, we report the preparation of several new tetrahydro [60] fullerene epoxides and investigation of their chemical reactivity.

RESULTS AND DISCUSSION

In our previous work, we have shown that the epoxy moiety in $C_{60}(O)(OOtBu)_4$ can be opened selectively by various

nucleophiles to form the hexaadduct $C_{60}(OH)Nu(OOtBu)_4$, 11 which can be further converted to other fullerene derivatives including open-cage fullerenes ¹² and azafullerenes. ¹³ In an attempt to extend the epoxy opening reactions to other tetrahydro[60]fullerene epoxides, we tested the reactivity of the tetraamino C₆₀ epoxides. All our efforts failed to produce any new compound selectively. The amino addends can be partially eliminated from the fullerene cage under the conditions, thus resulting in a complex mixture of products. To avoid the undesirable side effect of the amino addends, the number of amino addends should be reduced. Therefore, we prepared the tetrahydro epoxy products 3-6 starting from 1,4-bisadducts 1 and 2 (Scheme 1).14,15

Compounds 1 and 2 were prepared according to the literature procedure. 14 Their reactions with 4-methylpiperidine afforded a mixture of two isomers in both cases. The amination conditions shown in Scheme 1 are the same as those developed by Nakamura et al. for the amination reaction of C_{60} . ^{4c²} As expected, the 1,4-bisadducts are more reactive than C_{60} . The present reaction time is about 3 h, whereas the reaction of C₆₀ needs more than 10 h. Other secondary amines can also react with 1 and 2 to form a mixture of isomers. For example, the reaction of piperidine with 2 afforded 5a and 6a, which are analogous to the 4-methylpiperidine products 5 and 6. We chose the 4-methylpiperidine because of its better solubility and characteristic methyl group for NMR characterization.


Structural assignments of the isomers 5 and 6 were based on their different symmetry shown on the NMR spectra. To assign structures of the C_1 symmetric compounds 3 and 4, single crystals of compound 4 were obtained from slow evaporation of

Received: February 6, 2015 Published: March 17, 2015

[‡]State Key Laboratory of Organometallic Chemistry, Shanghai Institute of Organic Chemistry, Shanghai 200032, China

The Journal of Organic Chemistry

Scheme 1. Amination Reactions of 1,4-C₆₀ Adducts



its solution in CDCl₃. The structure shows four pairs of enantiomers in the unit cell. The epoxy moieties in each pair of enantiomers are in close contact, forming dimeric structures (Figure 1). The bond distances and bond angles are virtually the same between the phenyl bound cage carbon and the corresponding 4-methylpiperidine bound cage carbon next to the epoxy moiety, indicating that the different addends have no effect on the cage structure. The cyclopentadienyl double bonds (3.51 Å) surrounded by the addends are the shortest on the cage.

Possible pathways for the formation of compounds 3-6 are shown in Scheme 2. The initial single electron transfer step to form $\bf A$ and formation of the aziridinium moiety in intermediates $\bf D$ and $\bf F$ are the same as in the amination reaction of pristine C_{60} . 4c,15c Formation of compound $\bf 3$ with the epoxy group far away from the phenyl group may go through intermediates $\bf A$, $\bf B$, and $\bf C$, in which process the hydroxyl group is replaced by an amino group through an S_N2' mechanism. Amino groups could be replaced by more reactive amines through an S_N2' mechanism as reported by Troshin et al. 16 Addition of the aminium group in the *para* position of the OH group in $\bf B$ would lead eventually to a hydroxyl group





Figure 1. X-ray structure of compound **4.** Ellipsoids were drawn at 50%. For clarity, hydrogen atoms were not drawn. Color scheme: gray = C, blue = N, red = O.

containing tetrahydro [60] fullerene epoxide, but no such product was isolated perhaps due to further reactions to form more complex products. Compound 4 can also be formed through intermediates D and E besides C, which probably is responsible for the higher yield of 4 compared to that of 3. The formation of compounds 5 and 6 may go through intermediate F, which can be formed in a similar pathway to intermediate D. The higher yield of 6 indicates that the $S_{\rm N}2^{\prime\prime}$ pathway is more efficient than the $S_{\rm N}2^{\prime\prime}$ pathway.

With the aryl group mixed aminofullerene epoxides in hand, we then investigated the chemical reactivity of their epoxy moiety (Scheme 3). Indeed, introduction of aryl groups improves the selectivity and results in reactions analogous to those for the tetraperoxo C_{60} epoxide $C_{60}(O)(OOtBu)_4$. Treatment of **6** with ferric chloride in toluene afforded the hexaadduct 7 with the addition of another tolyl addend. ^{15b,17} Hydroxyl and alkoxyl groups were added by using ptoluenesulfonic acid as the catalyst. The epoxide opening reactions are highly regioselective, producing only the product with the hydroxyl group on the central pentagon. 11 The vicinal diol moiety in 8a can be easily converted to the open-cage diketone 9 with diacetoxyliodobenzene. 18 The 10-membered orifice in 9 could be closed to form isomers 10a and 10b by treating it with methanol in the presence of BF₃. This orifice closing reaction is different from the analogous reaction of $C_{60}(O)_2(OOtBu)_4$ with methanol, which gave just one product with the hydroxyl group on the central pentagon. 18 Considering such a result, we assigned the major product 10a with the

The Journal of Organic Chemistry


Scheme 2. Possible Pathways of Amination Reactions of 1,4- C_{60} Adducts



hydroxyl group on the central pentagon. ¹⁹ The epoxy moiety in compounds 3, 4, and 5 could also be hydrolyzed to the vicinal diols 11, 12, and 13, and then oxidized into the corresponding open-cage diketone compounds 14, 15, and 16, respectively (Figure 2).

Spectroscopic data of compounds 7-16 are in agreement with the structures depicted in Scheme 3 and Figure 2. All the compounds except diol 13 and diketone 16 are C_1 symmetric and showed the expected NMR pattern, in particular, on the ¹³C NMR spectra, which showed the expected number of fullerene skeleton carbon signals. Assignments of the hydroxyl group on the central pentagon for compounds 7 and 8 assumed that there is no OH shift in the epoxy opening process. This is well supported by the fact that oxidation of diols 8a, 11, 12, and 13 led to the corresponding diketones. Compounds 10a and 10b showed two characteristic acetal signals at 106. 48, 107.73 ppm and 102.94, 110.35 ppm, respectively, confirming the presence of the diacetal moiety. However, the NMR data cannot distinguish the isomers and the assignment could be switched. The open-cage compounds 9, 14, 15, and 16 showed the expected carbonyl carbon signals on the ¹³C NMR spectra.

Scheme 3. Epoxy Opening Reactions and Preparation of Open-Cage Compounds a



^aThe assignment of 10a and 10b is not conclusive and may be reversed.

Their IR spectra showed strong carbonyl stretching at around $1743~{\rm cm}^{-1}$.

Elimination of the epoxy moiety and partial elimination of the amino addends can be effectively achieved with excess PPh_3/I_2 for compounds 3 and 5, as shown in Scheme 4. Complete removal of all the addends and formation of C_{60} was observed when $C_{60}(O)(NR_2)_4$ (NR_2 = 4-methylpiperidinyl) was treated with PPh_3/I_2 . Triphenylphosphine has been reported before to remove the epoxy moiety in fullerene epoxides $C_{60}(O)_n$. In the present case, triphenylphosphine alone could not eliminate the amino nor epoxy addends. Both iodine and triphenylphosphine are needed for the retroamination addition process. Treating the open-cage compounds such as 9 with PPh_3/I_2 yielded a complex mixture of unidentified products. The 1,4-adduct 17^{21} reacted with 4-methylpiperidine

The Journal of Organic Chemistry





Figure 2. Structure of compounds 11-16.

Scheme 4. Selective Removal of Amino and Epoxy Addends



to give compounds 3 and 4, which supports the formation of intermediate C in the proposed mechanism in Scheme 2.

CONCLUSION

Similar to pristine C_{60} , aryl 1,4-[60] fullerene adducts react with secondary amines to form amino and aryl-mixed tetrahydro[60] fullerene epoxides in good yields. Introduction of the aryl group greatly improves the chemical reactivity of the epoxy moiety in comparison to the tetraamino[60] fullerene epoxides. Hydrolysis of the epoxy moiety in the mixed tetrahydro[60] fullerene epoxides yields the vicinal diol moiety, which can be oxidized into the open-cage diketones with a 10-membered orifice. In addition, PPh_3/I_2 has been shown to facilitate a retroamination process for the tetrahydro[60]-fullerene epoxides. The present method may be applied to prepare other mixed tetrahydro[60] fullerene epoxides.

EXPERIMENTAL SECTION

All reagents were used as received. Dichloromethane (DCM) was distilled from phosphorus pentoxide. Benzene was distilled from sodium. Other solvents were used as received. The reactions were carried out under atmosphere condition. The NMR spectra were

obtained at 25 °C (except noted) with 400 and 500 MHz spectrometers (1 H and 13 C NMR spectra of the same compound were obtained with different spectrometers in some cases). Chemical shifts are given in ppm relative to TMS or CDCl₃ (for 13 C NMR). ESI-FT-ICR-HRMS spectra were recorded in the positive-mode. Chromatographic purifications were carried out with silica gel of 200–300 mesh.

Preparation of Compounds 3 and 4. To a solution of compound 1 (132 mg, 0.162 mmol) in 80 mL of PhCl was added DMSO (16 mL), and the mixture was stirred under continuous bubbling of O₂ for 10 min. To the solution was then added 4-methylpiperidine (96 mg, 0.97 mmol), and the mixture was stirred under an atmospheric pressure of O₂ at 25 °C for 3 h. The mixture was washed with saturated aqueous NH₄Cl (100 mL) twice. The organic layer was washed further with water three times and dried over anhydrous Na₂SO₄. The solution was chromatographed on a silica gel column eluting with DCM. Compound 3 was collected and evaporated as an orange solid (56 mg, 0.051 mmol, 31%). The eluting solvent was changed to DCM/ethyl acetate (500:1), and another red band was eluted to give compound 4 (74 mg, 0.067 mmol, 41%) as an orange solid.

Characterization Data for **3**. ¹H NMR (400 MHz, CDCl₃) δ: 8.31 (d, 2H, J = 7.4 Hz), 7.47 (dd, 2H, J1 = 7.1 Hz, J2 = 7.4 Hz), 7.38 (t, J2 = 7.4 Hz)1H, J = 7.0 Hz), 3.82 (d, 1H, J = 10.8 Hz), 3.64–3.59 (m, 4H), 3.51 (d, 1H, J = 10.1 Hz), 2.75 (t, 1H, J = 11.3 Hz), 2.68–2.59 (m, 5H), 1.83-1.61 (m, 9H), 1.42-1.32 (m, 6H), 0.97 (s, br, 9H). ¹³C NMR (125 MHz, CDCl₂) (all signals represent 1C except noted) δ : 152.55. 152.46, 151.91, 151.58, 150.32, 149.95, 149.68, 149.29, 149.12, 149.05, 148.99, 147.82, 147.78, 147.77 (2C), 147.65 (2C), 147.46, 147.37, 147.24 (2C), 147.20, 147.12 (2C), 147.07, 146.97, 146.93, 146.87, 146.46, 146.41, 146.34, 145.73, 145.69, 145.59, 145.37, 145.07, 145.02, 144.62, 144.32, 144.15, 143.78, 143.74, 143.72, 143.71, 143.59, 143.53, 143.47, 143.02, 142.96, 142.85, 141.92, 140.59, 140.38, 140.11, 138.47, 128.92 (2C), 128.58 (2C), 127.58, 76.84, 76.82, 76.19, 72.66, 71.28, 59.64, 51.82, 51.67, 51.44, 51.20, 51.17, 50.76, 35.25 (2C), 35.22 (2C), 35.20, 35.15, 30.84, 30.63, 30.57, 21.97 (3C). ESI-FT-ICR-HRMS-Positive: $C_{84}H_{42}N_3O$ (M + H⁺) calculated 1108.3322, found 1108.3346.

Characterization Data for **4**. 1 H NMR (400 MHz, CDCl₃) δ : 8.02 (d, 2H, J = 7.5 Hz), 7.44 (dd, 2H, J1 = 7.6 Hz, J2 = 7.6 Hz), 7.34 (t, J2 = 7.5 Hz)1H, J = 7.3 Hz), 3.86 (d, 1H, J = 11.1 Hz), 3.78 (d, 1H, J = 10.8 Hz), 3.68-3.65 (m, 3H), 3.48 (d, 1H, J = 10.1 Hz), 2.87-2.61 (m, 6H), 2.37 (t, 1H, J = 10.6 Hz), 1.87 - 1.70 (m, 6H), 1.57 - 1.47 (m, 3H), 1.39-1.30 (m, 6H), 1.01 (dd, 6H, J1 = 6.5 Hz, J2 = 9.0 Hz), 0.94 (d, 3H, J = 6.1 Hz). ¹³C NMR (125 MHz, CDCl₃) (all signals represent 1C except noted) δ : 154.85, 154.73, 152.14, 150.96, 150.55, 149.31, 149.27, 148.98, 148.86, 147.93, 147.82, 147.77, 147.69, 147.47, 147.39, 147.24, 147.12, 147.05, 147.04, 147.00, 146.97, 146.95, 146.93, 146.84, 146.77, 146.74, 146.63, 146.36, 146.25, 146.18, 146.07, 145.79, 145.44, 145.28, 145.16, 145.12, 145.02, 144.61, 144.24, 143.96, 143.91, 143.90, 143.83, 143.78, 143.63, 143.51, 143.39, 142.98, 142.91, 142.84, 140.50, 140.42, 139.63, 137.96, 128.85 (2C), 128.42 (2C), 127.53, 76.28, 76.00, 72.57, 72.50, 72.12, 62.23, 51.80, 51.42, 51.31, 50.96, 50.92, 50.48, 35.32, 35.22 (4C), 35.15, 35.12, 30.94, 30.77, 30.63, 22.03, 21.98, 21.96. ESI-FT-ICR-HRMS-Positive: $C_{84}H_{42}N_3O$ (M + H⁺) calculated 1108.3322, found 1108.3333.

Single crystals of 4 were obtained from slow evaporation of its CDCl₃ solution. Formula: $C_{84}H_{41}N_3O$, T=180.00(10) K, monoclinic, space group C2/c. Unit cell dimensions: a=34.1629(8) Å, b=20.3663(4) Å, c=19.4299(3) Å, $\alpha=\gamma=90^\circ$, $\beta=104.204(2)^\circ$. V=13105.5(5) Å³. Z=8, $\rho_{\rm calcd}=1.123$ Mg/m³. Reflections collected/unique 96995/12884 [$R({\rm int})=0.0511$]. Final R indices [$I>2\sigma(I)$], $R_1=0.0817$, w $R_2=0.2481$ [all data]. Crystallographic data have been deposited in the Cambridge Crystallographic Data Centre as deposition number CCDC-1046797

Preparation of Compounds 5 and 6. To a solution of compound 2 (250 mg, 0.277 mmol) in 90 mL of PhCl was added DMSO (18 mL), and the mixture was stirred under continuous bubbling of O_2 for 10 min. To the solution was then added 4-methylpiperidine (165 mg, 1.66 mmol), and the mixture was stirred

under an atmospheric pressure of O_2 at 25 °C for 3 h. The mixture was washed with saturated aqueous NH₄Cl (100 mL) twice. The organic layer was washed further with water three times and dried over anhydrous Na₂SO₄. The solution was chromatographed on a silica gel column eluting with toluene/CS₂ (1:1). Compound 5 was collected and evaporated as an orange solid (79 mg, 0.071 mmol, 26%). The eluting solvent was changed to toluene/ethyl acetate (500:1), and another red band was eluted to give compound 6 (128 mg, 0.115 mmol, 41%) as an orange solid.

Characterization Data for **5**. ¹H NMR (500 MHz, CDCl₃) δ: 7.89 (d, 4H, J = 8.0 Hz), 7.67 (d, 4H, J = 7.9 Hz), 3.64 (d, 2H, J = 11.0 Hz), 3.54 (d, 2H, J = 12.2 Hz), 2.64–2.58 (m, 4H), 2.37 (s, 6H), 1.77–1.70 (m, 4H), 1.41–1.38 (m, 6H), 0.99 (d, 6H, J = 5.9 Hz). ESI-FT-ICR-HRMS-Positive: $C_{86}H_{39}N_2O$ (M + H⁺) calculated: 1115.3057, found: 1115.3036. (^{13}C NMR for the compound could not be obtained due to low solubility).

Characterization Data for **6**. ¹H NMR (500 MHz, CDCl₃) δ : 7.82 (d, 2H, J = 8.0 Hz), 7.67 (d, 2H, J = 8.0 Hz), 7.14 (dd, 4H, J1 = 7.9)Hz, J2 = 13.5 Hz), 3.77 (d, 1H, J = 11 Hz), 3.67 (m, 2H), 3.54 (d, 1H, J = 10.7 Hz, 2.77 (t, 1H, J = 10.6 Hz), 2.71–2.60 (m, 2H), 2.54–2.50 (m, 1H), 2.37 (s, 3H), 2.36 (s, 3H), 1.83 (d, 1H, I = 12.1 Hz), 1.74 (t, 3H, J = 11.4 Hz), 1.62 (d, 1H, J = 12.0 Hz), 1.36–1.30 (m, 5H), 0.97 (dd, 6H, J1 = 6.6 Hz, J2 = 6.6 Hz). ¹³C NMR (125 MHz, CDCl₃) (all signals represent 1C except noted) δ : 156.42, 152.39, 152.35, 151.02, 150.89, 150.18, 149.39, 149.29, 149.12, 148.94, 148.90, 148.01, 147.84, 147.77, 147.74 (2C), 147.65, 147.50, 147.34, 147.20, 147.19, 147.17, 147.10, 147.07, 146.99, 146.82, 146.81, 146.61, 146.43, 146.37, 146.28, 146.22, 145.54, 145.43, 145.42, 145.15, 145.04, 144.97, 144.65, 144.55, 144.01, 144.00, 143.77 (2C), 143.61, 143.52, 143.46, 143.34, 142.95, 142.90, 141.09, 140.54, 140.34, 137.78, 137.35, 137.32, 136.85, 136.22, 129.63 (2C), 129.43 (2C), 128.08 (4C), 76.41, 76.06, 72.76, 72.05, 62.39, 59.20, 51.84, 51.46, 51.14, 50.78, 35.20 (3C), 35.16, 30.80, 30.64, 21.96 (2C), 21.15, 21.14. ESI-FT-ICR-HRMS-Positive: $C_{86}H_{39}N_2O$ (M + H⁺) calculated: 1115.3057, found: 1115.3072.

Preparation of Compounds 5a and 6a. To a solution of compound 2 (620 mg, 0.687 mmol) in 200 mL of PhCl was added DMSO (40 mL), and the mixture was stirred under continuous bubbling of O2 for 10 min. To the solution was then added piperidine (350 mg, 4.12 mmol), and the mixture was stirred under an atmospheric pressure of O2 at 25 °C for 3 h. The mixture was washed with saturated aqueous NH₄Cl (100 mL) twice. The organic layer was washed further with water three times and dried over anhydrous Na2SO4. The solution was chromatographed on a silica gel column eluting with toluene/CS2 (1:1). Compound 5a was collected and evaporated as an orange solid (209 mg, 0.192 mmol, 28%). The eluting solvent was changed to toluene/ethyl acetate (500:1), and another red band was eluted to give compound 6a (314 mg, 0.289 mmol, 42%) as an orange solid. Due to poor solubility, characterization data of 5a could not be obtained. Characterization data for 6a: ¹H NMR (500 MHz, $CS_2/CDCl_3$) δ : 7.79 (d, 2H, J = 7.9 Hz), 7.61 (d, 2H, J = 7.9 Hz), 7.11 (dd, 4H, J1 = 8.4 Hz, J2 = 10.2 Hz), 3.19-3.12(m, 8H), 2.35 (s, 6H), 1.71–1.68 (m, 8H), 1.52–1.51 (m, 4H). ¹³C NMR (125 MHz, CS₂/CDCl₃) (all signals represent 1C except noted) δ: 156.28, 152.50, 152.34, 150.62, 150.51, 149.67, 149.15 (2C), 148.97, 148.81, 148.77, 147.87, 147.77, 147.62, 147.60, 147.49 (2C), 147.34, 147.16, 147.05, 147.04 (2C), 146.95, 146.93, 146.84, 146.65 (2C), 146.49, 146.30, 146.21, 146.12, 146.08, 145.26, 145.24, 145.23, 145.07, 144.99, 144.88, 144.46, 144.43, 143.92, 143.86, 143.67, 143.61, 143.49, 143.36, 143.30, 143.23, 142.81 (2C), 141.03, 140.53, 139.91, 137.64, 137.04, 136.98, 136.69, 135.93, 129.49 (2C), 129.30 (2C), 128.07 (2C), 127.92 (2C), 76.34, 75.88, 72.81, 71.87, 62.20, 59.05, 52.16 (2C), 51.46 (2C), 27.01 (2C), 26.96 (2C), 24.74, 24.57, 21.10 (2C). ESI-FT-ICR-HRMS-Positive: C₈₄H₃₅N₂O (M + H⁺) calculated: 1087.2744, found: 1087.2730.

Preparation of Compound 7. To a solution of compound 6 (290 mg, 0.260 mmol) in 80 mL of toluene was added $FeCl_3$ (253 mg, 1.56 mmol), and the mixture was stirred at 35 °C for 20 h. The solution was washed with saturated aqueous NaHCO₃ (100 mL) twice. The organic layer was washed further with water three times and dried over anhydrous Na₂SO₄. The solution was chromatographed on a silica gel

column eluting with toluene. Compound 7 was collected and evaporated as an orange solid (235 mg, 0.195 mmol, 75%).

Characterization Data for **7**. 1 H NMR (400 MHz, CDCl₃) δ : 7.88 (s, 2H), 7.59 (s, 2H), 7.22–7.17 (m, 6H), 7.00 (s, 2H), 3.92 (s, 2H), 3.53 (s, 1H), 3.10-3.05 (m, 2H), 2.75 (d, 2H, I = 7.4 Hz), 2.57 (s, 1H), 2.38 (s, 6H), 2.27 (s, 3H), 1.96-1.85 (m, 3H), 1.59-1.18 (m, 7H), 1.03 (s, 3H), 0.84 (s, 3H). ¹³C NMR (125 MHz, CDCl₂) (all signals represent 1C except noted) δ : 154.54, 154.10, 153.72, 153.54, 152.59, 152.41, 150.38, 148.83 (2C), 148.73, 148.67, 148.61 (2C), 148.57, 148.56, 148.54, 148.50, 148.44, 148.25, 148.23, 147.99, 147.90, 147.57, 147.47, 147.43, 147.35, 147.29, 147.27, 147.25, 146.92, 146.66, 145.47, 145.30, 145.28, 145.04, 144.99, 144.96, 144.79, 144.74 (2C), 144.67, 144.54, 144.38, 144.19, 143.72, 143.64, 143.30, 143.24, 143.21, 142.72, 142.08, 141.69, 141.58, 139.63, 138.34, 137.34, 137.07, 137.04, 137.01, 136.47, 130.54, 129.54 (3C), 129.48 (2C), 129.41 (2C), 128.58 (2C), 127.43 (2C), 84.79, 74.04, 71.07, 63.19, 61.07, 58.12, 51.70, 51.65, 50.33, 50.17, 35.67, 35.58, 35.21, 35.14, 31.18, 30.52, 22.14, 21.98, 21.28, 21.20, 21.13. ESI-FT-ICR-HRMS-Positive: $C_{93}H_{47}N_2O$ (M + H⁺) calculated 1207.3683, found 1207.3651.

Preparation of Compound 8a. p-Toluenesulfonic acid monohydrate (140 mg, 0.736 mmol) was added to compound 6 (164 mg, 0.147 mmol) in 80 mL of toluene. The resulting solution was stirred at 80 °C for about 18 h. The solution was washed with saturated aqueous NaHCO₃ (100 mL) twice. The organic layer was washed further with water three times and dried over anhydrous Na2SO4. The organic layer was directly chromatographed on a silica gel column eluting with toluene to give some compound 2 and some compound 7 (45 mg, 0.037 mmol, 5%). The eluting solvent was changed to toluene/ethyl acetate (50:1) to remove unknown impurities. Then, the eluent was changed to toluene/ethyl acetate (10:1). The first red band was some byproducts. The second red band was eluted with CS₂/toluene/ethyl acetate (1:2:4) to afford fullerenol 8a (95 mg, 0.084 mmol, 57%). Characterization data for 8a: ESI-FT-ICR-HRMS-Positive: $C_{86}H_{41}N_2O_2$ (M + H)⁺ calculated 1133.3163, found 1133.3133. (NMR spectra for 8a could not be obtained due to low solubility)

Preparation of Compound 8b. p-Toluenesulfonic acid monohydrate (316 mg, 1.66 mmol) and CH₃OH (15 mL) were added to compound 6 (185 mg, 0.166 mmol) in 60 mL of chlorobenzene. The resulting solution was stirred at 80 $^{\circ}\text{C}$ for about 10 h. The solution was washed with saturated aqueous NaHCO₃ (100 mL) twice. The organic layer was washed further with water three times and dried over anhydrous Na₂SO₄. The organic layer was directly chromatographed on a silica gel column eluting with toluene to give some compound 2 and some unreacted compound 6 (84 mg, 0.075 mmol). The eluting solvent was still toluene to remove unknown impurities. Then, the eluent was changed to toluene/ethyl acetate (100:1). The first red band was compound 8b (80 mg, 0.070 mmol, 42%, based on recovered starting material 77%). Characterization data for 8b: ¹H NMR (400 MHz, CDCl₃) δ : 7.78 (d, 2H, J = 7.5 Hz), 7.74 (d, 2H, J = 7.5 Hz), 7.17 (d, 2H, I = 7.4 Hz), 7.12 (d, 2H, I = 7.4 Hz), 5.02 (s, 1H), 3.90 (s, 3H), 3.81 (d, 1H, J = 12.9 Hz), 3.72 (d, 1H, J = 10.2 Hz), 3.66 (d, 1H, J = 10.6 Hz), 3.35 (d, 1H, J = 10.2 Hz), 2.75 (t, 1H, J = 10.2 Hz) 10.6 Hz), 2.67-2.58 (m, 2H), 2.37 (s, 6H), 2.17 (t, 1H, J = 10.5 Hz), 1.78 (s, br, 2H), 1.68 (d, 1H, J = 8.1 Hz), 1.47 - 1.20 (m, 7H), 0.98 (d, 3H, J = 5.7 Hz), 0.91 (d, 3H, J = 4.4 Hz). ¹³C NMR (125 MHz, 50 °C, CDCl₃) (all signals represent 1C except noted) δ : 154.19, 153.76, 153.67, 152.86, 152.32, 151.30, 149.22, 148.96 (3C), 148.95, 148.86, 148.81 (2C), 148.77, 148.70, 148.69, 148.63, 148.44, 148.31 (2C), 148.16 (2C), 147.75, 147.67, 147.58, 147.49, 147.47, 147.42, 146.61, 146.49, 145.90, 145.81, 145.37, 145.22, 145.04, 144.92, 144.79 (2C), 144.72, 144.48, 144.22, 144.10, 143.99, 143.64, 143.61, 143.50 (2C), 143.28, 143.23, 143.17, 143.14, 142.90, 142.62, 137.39, 137.36, 136.59, 135.87, 129.62 (2C), 129.48 (2C), 128.50 (2C), 128.30 (2C), 83.56, 82.03, 74.64, 71.67, 60.50, 58.25, 56.37, 51.92, 51.54, 51.38, 50.36, 35.54, 35.43, 31.02, 30.83, 22.05 (2C), 21.24 (2C). ESI-FT-ICR-HRMS-Positive: $C_{87}H_{43}N_2O_2$ (M + H)⁺ calculated 1147.3319, found

Preparation of Compound 8c. p-Toluenesulfonic acid monohydrate (546 mg, 2.87 mmol) and C_2H_5OH (15 mL) were added to compound 6 (320 mg, 0.287 mmol) in 100 mL of toluene. The

resulting solution was stirred at 80 °C for about 25 h. The solution was washed with saturated aqueous NaHCO₃ (100 mL) twice. The organic layer was washed further with water three times and dried over anhydrous Na2SO4. The organic layer was directly chromatographed on a silica gel column eluting with toluene to give some compound 2 and some unreacted compound 6 (145 mg, 0.130 mmol). The eluting solvent was still toluene to remove unknown impurities. Then, the eluent was changed to toluene/ethyl acetate (100:1). The first red band was compound 8c (132 mg, 0.114 mmol, 40%, based on recovered starting material 73%). Characterization data for 8c: ¹H NMR (400 MHz, CDCl₃) δ : 7.74 (dd, 4H, J = 8.9 Hz), 7.13 (dd, 4H, J1 = 7.3 Hz, J2 = 19.5 Hz), 5.13 (s, 1H), 4.25-4.22 (m, 1H), 4.16-4.12 (m, 1H), 3.79 (d, 1H, J = 9.5 Hz), 3.72 (d, 1H, J = 9.9 Hz), 3.62(d, 1H, J = 9.3 Hz), 3.31 (d, 1H, J = 9.2 Hz), 2.76 (t, 1H, J = 10.4 Hz),2.67-2.51 (m, 2H), 2.36 (s, 6H), 2.13 (t, 1H, J = 9.8 Hz), 1.77 (s, br, 1H), 1.65 (d, 1H, I = 7.1 Hz), 1.42–1.36 (m, 8H), 1.25–1.20 (m, 3H), 0.98 (d, 3H, J = 4.8 Hz), 0.90 (s, 3H). ¹³C NMR (125 MHz, CDCl₃) (all signals represent 1C except noted) δ : 153.84, 153.62, 153.29, 152.77, 152.03, 151.14, 148.93, 148.68 (3C), 148.59, 148.53 (2C), 148.51, 148.46, 148.45, 148.36, 148.16, 148.04 (2C), 147.87, 147.62, 147.47, 147.39, 147.34, 147.23, 147.20, 147.15, 146.57, 146.30, 146.11, 145.68, 145.06, 144.87, 144.81, 144.74, 144.59, 144.55, 144.51, 144.26, 144.01, 143.91, 143.82, 143.75, 143.42 (2C), 143.21, 143.07, 142.98 (2C), 142.84, 142.64 (2C), 142.32, 137.17, 137.12, 136.27, 135.61, 129.45 (2C), 129.35 (2C), 128.31 (2C), 128.05 (2C), 83.05, 81.41, 74.37, 71.38, 64.59, 60.23, 57.95, 51.79, 51.43, 51.20, 50.16, 35.33, 35.24 (3C), 30.86, 30.65, 22.02 (2C), 21.21 (2C), 15.90. ESI-FT-ICR-HRMS-Positive: $C_{88}H_{45}N_2O_2$ (M + H)⁺ calculated 1161.3476, found 1161.3469.

Preparation of Compound 9. To a solution of compound 8a (177 mg, 0.156 mmol) in 50 mL of dry benzene was added DIB (diacetocyliodobenzene) (101 mg, 0.313 mmol). The resulting solution was stirred at 35 °C for 45 min. The organic layer was directly chromatographed on a silica gel column eluting with toluene/ ethyl acetate (100:1). The first red band was collected as compound 9 (150 mg, 0.133 mmol, 85%). Characterization data for 9: ¹H NMR (500 MHz, CDCl₃) δ : 7.76 (d, 2H, J = 7.5 Hz), 7.60 (d, 2H, J = 7.5Hz), 7.19 (d, 2H, J = 7.4 Hz), 7.11 (d, 2H, J = 7.4 Hz), 3.79 (d, 1H, J= 10.3 Hz), 3.66 (d, 1H, J = 9.2 Hz), 3.53 (d, 1H, J = 9.6 Hz), 3.18 (d, 1H, J = 9.4 Hz), 2.86 (t, 1H, J = 10.5 Hz), 2.73 (t, 1H, J = 11.0 Hz), 2.48 (t, 1H, J = 10.7 Hz), 2.36 (s, 3H), 2.35(s, 3H), 2.28 (t, 1H, J =11.1 Hz), 1.81 (m, 2H), 1.65-1.62 (m, 1H), 1.49-1.47 (m, 2H), 1.36-1.31 (m, 3H), 1.23-1.18 (m, 2H), 0.97 (d, 3H, J = 5.6 Hz), 0.90(d, 3H, I = 5.5 Hz). ¹³C NMR (125 MHz, CDCl₃) (all signals represent 1C except noted) δ : 201.74, 199.53, 152.77, 152.11, 152.04, 150.54, 149.60, 149.27 (2C), 149.24, 149.16, 149.02, 149.00, 148.98, 148.82, 148.73, 148.64, 148.55, 148.47, 148.39, 148.24 (2C), 147.93, 147.85, 147.54, 147.40, 146.74, 146.71, 146.12, 145.19, 145.04, 144.92 (2C), 144.78, 144.64, 144.54, 143.52 (2C), 143.18, 143.09, 142.92, 142.80, 142.70, 142.67, 142.55, 142.53, 141.60, 140.97 (2C), 140.65, 140.23, 140.04, 139.69, 137.88, 137.73, 135.28, 134.62 (2C), 129.66 (4C), 128.39 (2C), 127.52 (2C), 81.89, 69.45, 66.31, 56.24, 52.57, 52.37, 51.43, 50.16, 35.03, 34.96, 34.91, 34.88, 30.52, 30.35, 21.83, 21.77, 21.16, 21.11. FT-IR (microscope): 3025, 2949, 2921, 2870, 2810, 1743, 1722, 1511, 1461, 1377, 1279, 1261, 1205, 1159, 1107, 1105, 1079, 1021, 974, 887, 845, 818, 757, 729, 695 cm⁻¹. ESI-FT-ICR-HRMS-Positive: $C_{86}H_{39}N_2O_2$ (M + H)⁺ calculated 1131.3006, found 1131.3021.

Preparation of Compound 10a and 10b. Boron trifluoride ethyl ether complex (678 mg, 9.97 mmol, 0.6 mL) was added to compound 9 (324 mg, 0.287 mmol) in 80 mL of dry DCM and 15 mL of MeOH. The resulting solution was stirred at 40 °C for about 1.5 h. The solution was washed with saturated aqueous NaHCO₃ (100 mL) twice. The organic layer was washed further with water three times and dried over anhydrous Na₂SO₄. The organic layer was directly chromatographed on a silica gel column eluting with toluene/ethyl acetate (100:1) to remove two black bands which could not be characterized. Then, the eluent was changed to toluene/ethyl acetate (40:1). The first red band was compound 10b (87 mg, 0.075 mmol,

26%). The second red band was eluted with toluene/ethyl acetate (20:1) to afford compund 10a (124 mg, 0.107 mmol, 37%).

Characterization Data for **10a**. ¹H NMR (500 MHz, CDCl₃/CS₂) δ : 7.74 (d, 2H, J = 7.8 Hz), 7.68 (d, 2H, J = 7.8 Hz), 7.15–7.14 (m, 4H), 4.15 (s, 1H, OH), 3.80 (s, 3H, OCH₃), 3.73 (s, br, 2H), 3.60 (d, 1H, J = 10.2 Hz), 3.35 (d, 1H, J = 10.3 Hz), 2.67 (dd, 2H, J1 = 9.9 Hz, J2 = 20.7 Hz), 2.53 (t, 1H, J = 10.5 Hz), 2.37 (s, 3H), 2.36 (s, 3H), 2.19 (t, 1H, J = 10.5 Hz), 1.78 (d, 2H, J = 11.6 Hz), 1.68 (d, 1H, J = 10.5 Hz) 11.4 Hz), 1.59-1.46 (m, 2H), 1.39-1.32 (m, 3H), 1.24-1.22 (m, 1H), 0.98 (d, 3H, J = 6.0 Hz), 0.91 (d, 3H, J = 5.7 Hz). ¹³C NMR (125 MHz, CDCl₃/CS₂) (all signals represent 1C except noted) δ : 159.56, 159.19, 151.82, 150.19, 149.34, 149.30, 149.17, 149.07, 148.97, 148.92, 148.90, 148.86, 148.67, 148.50 (2C), 148.42, 148.40, 148.25, 148.19, 148.17, 148.13, 147.97, 147.89, 147.42, 147.34, 147.05, 147.03, 146.99, 146.65, 146.39, 146.18, 145.95, 145.49, 144.90, 144.70 (2C), 144.60, 144.16, 144.05, 143.61, 143.50, 143.38, 143.32, 143.23, 142.58, 142.55, 142.48, 141.95, 141.64, 141.36 (2C), 140.99, 140.94, 137.41, 137.34, 136.89, 136.18 (2C), 129.83, 129.59, 127.87, 127.71, 107.73, 106.48, 80.99, 69.30, 65.99, 56.28, 54.33, 52.40, 51.81, 51.19, 50.00, 35.33, 35.28, 35.22 (2C), 30.93, 30.81, 22.08, 22.04, 21.26, 21.22. ESI-FT-ICR-HRMS-Positive: $C_{87}H_{43}N_2O_3 (M + H)^+$ calculated 1163.3268, found 1163,3261.

Characterization Data for **10b**. ¹H NMR (500 MHz, CDCl₃/CS₂/ CD₃OD) δ : 7.74 (d, 2H, I = 6.3 Hz), 7.54 (d, 2H, I = 6.2 Hz), 7.21 (d, 2H, J = 6.0 Hz), 7.12 (d, 2H, J = 5.8 Hz), 3.74 (d, 1H, J = 9.3 Hz), 3.67 (d, 1H, J = 8.9 Hz), 3.49 (s, 3H, OCH₃), 3.43 (s, 1H, OH), 3.25 (d, 1H, J = 8.6 Hz), 2.71-2.65 (m, 2H), 2.49-2.47 (m, 1H), 2.42 (s, 3H), 2.34 (s, 3H), 1.94–1.92 (m, 1H), 1.78 (dd, 2H, J1 = 12.3 Hz, J2 = 21.2 Hz), 1.60 (d, 1H, J = 9.4 Hz), 1.47–1.36 (m, 5H), 1.18–1.14 (m, 3H), 0.98 (s, 3H), 0.86 (s, 3H). ¹³C NMR (125 MHz, CDCl₂/ CS_2/CD_3OD) (all signals represent 1C except noted) δ : 160.87, 158.57, 151.95, 150.19, 149.95, 149.27, 149.21, 149.17, 148.93, 148.92, 148.77 (2C), 148.56, 148.43, 148.42, 148.30 (2C), 148.24, 148.04, 147.98, 147.94, 147.85, 147.71, 147.22 (2C), 147.20 (2C), 147.07, 146.86, 146.50, 146.46, 146.22, 145.67, 145.30, 144.79, 144.67, 144.57, 144.41, 143.92, 143.36, 143.33, 143.17, 143.09, 143.06, 142.42 (2C), 142.32, 141.81, 141.67, 141.34, 140.82, 140.16, 138.39, 137.37, 137.20, 136.46, 135.98, 133.57, 129.41 (2C), 129.35 (2C), 129.01 (2C), 127.55 (2C), 110.35, 102.94, 80.46, 68.91, 66.38, 56.96, 55.86, 52.12, 51.26, 51.19, 49.75, 35.14, 35.07, 34.78, 34.62, 30.61, 30.49, 21.87, 21.82, 21.13, 21.02. ESI-FT-ICR-HRMS-Positive: C₈₇H₄₃N₂O₃ (M + H)⁺ calculated 1163.3268, found 1163.3271.

Compound 11. p-Toluenesulfonic acid monohydrate (424 mg, 2.23 mmol) was added to compound 3 (247 mg, 0.223 mmol) in 80 mL of toluene. The resulting solution was stirred at 80 °C for about 5 h. The solution was washed with saturated aqueous NaHCO₃ (100 mL) twice. The organic layer was washed further with water three times and dried over anhydrous Na₂SO₄. The organic layer was directly chromatographed on a silica gel column eluting with toluene to give some compound 17 and some unreacted starting material 3 (32 mg, 0.029 mmol). The eluting solvent was changed to toluene/ ethyl acetate (50:1) to remove unknown impurities. Then, the eluent was changed to toluene/ethyl acetate (10:1). The first red band was some byproducts. The second red band was eluted with CS₂/toluene/ ethyl acetate (1:2:4) to afford fullerenol 11 (168 mg, 0.149 mmol, 67%, based on recovered starting material 80%). Characterization data for 11: ¹H NMR (500 MHz, CDCl₃) δ : 8.21 (d, 2H, J = 4.8 Hz), 7.43 (s, 2H), 7.35 (d, 2H, J = 4.7 Hz), 5.93 (s, 2H, br, OH), 3.79-3.74 (m, J = 4.7 Hz), 5.93 (s, 2H, br, OH), 3.79-3.74 (m, J = 4.7 Hz), 5.93 (s, 2H, br, OH), 3.79-3.74 (m, J = 4.7 Hz), 5.93 (s, 2H, br, OH), 3.79-3.74 (m, J = 4.7 Hz), 5.93 (s, 2H, br, OH), 3.79-3.74 (m, J = 4.7 Hz), 5.93 (s, 2H, br, OH), 3.79-3.74 (m, J = 4.7 Hz), 5.93 (s, 2H, br, OH), 3.79-3.74 (m, J = 4.7 Hz), 5.93 (s, 2H, br, OH), 3.79-3.74 (m, J = 4.7 Hz), 5.93 (s, 2H, br, OH), 3.79-3.74 (m, J = 4.7 Hz), 5.93 (s, 2H, br, OH), 3.79-3.74 (m, J = 4.7 Hz), 5.93 (s, 2H, br, OH), 3.79-3.74 (m, J = 4.7 Hz), 5.93 (s, 2H, br, OH), 3.79-3.74 (m, J = 4.7 Hz), 5.93 (s, 2H, br, OH), 3.79-3.74 (m, J = 4.7 Hz), 5.93 (s, 2H, br, OH), 3.79-3.74 (m, J = 4.7 Hz), 5.93 (s, 2H, br, OH), 5.94H), 3.49 (s, 1H), 3.29 (s, 1H), 2.86 (m, 1H), 2.72-2.64 (m, 3H), 2.39 (m, 1H), 2.28 (m, 1H), 1.76 (d, 4H, J = 20.3 Hz), 1.56 (m, 1H), 1.47 (m, 2H), 1.31–1.29 (m, 7H), 1.16 (m, 1H), 0.92 (s, 6H), 0.88 (s, 3H). ¹³C NMR (125 MHz, CDCl₃) (all signals represent 1C except noted) δ : 154.96, 153.15, 151.27, 151.05, 150.95, 149.59, 149.28, 148.93, 148.86, 148.74 (3C), 148.63, 148.59, 148.48, 148.45, 148.40, 148.28 (3C), 148.21, 147.83 (2C), 147.68, 147.59, 147.51, 147.32 (3C), 147.26, 147.14, 146.06, 145.92, 145.86, 145.19, 145.10, 144.85, 144.74, 144.67, 144.65, 144.54, 144.51, 144.40, 144.10, 143.43, 143.07, 142.94, 142.74, 142.71, 142.66, 142.42, 142.40, 142.13, 141.36, 139.98, 139.82, 128.83 (2C), 128.53 (2C), 127.63 (2C), 82.07, 76.68, 74.37, 73.86, 71.34, 57.65, 51.50 (2C), 51.33, 51.16, 51.08, 50.12, 35.33,

35.25, 34.94 (3C), 34.84, 30.68, 30.54, 30.41, 22.04, 21.95, 21.93. ESI-FT-ICR-HRMS-Positive: $C_{84}H_{44}N_3O_2 \ (M + H)^+$ calculated 1126.3428, found 1126.3451.

Preparation of Compound 12. p-Toluenesulfonic acid monohydrate (196 mg, 1.03 mmol) was added to compound 4 (114 mg, 0.103 mmol) in 80 mL of toluene. The resulting solution was stirred at 80 °C for about 12 h. The solution was washed with saturated aqueous NaHCO₃ (100 mL) twice. The organic layer was washed further with water three times and dried over anhydrous Na2SO4. The organic layer was directly chromatographed on a silica gel column eluting with toluene to give some compound 17. Then, the eluent was changed to toluene/ethyl acetate (50:1) to remove unknown impurities. Then, the eluent was changed to toluene/ethyl acetate (10:1). The first red band was some byproduct. The second red band was eluted with CS₂/ toluene/ethyl acetate (1:2:4) to afford fullerenol 12 (79 mg, 0.070 mmol, 68%). Characterization data for 12: ESI-FT-ICR-HRMS-Positive: C₈₄H₄₄N₃O₂ (M + H)⁺ calculated 1126.3428, found 1126.3425. (NMR spectra for 12 could not be obtained due to low solubility)

Preparation of Compound 13. p-Toluenesulfonic acid monohydrate (158 mg, 0.831 mmol) was added to compound 5 (185 mg, 0.166 mmol) in 80 mL of toluene. The resulting solution was stirred at 80 °C for about 3 h. The solution was washed with saturated aqueous NaHCO₃ (100 mL) twice. The organic layer was washed further with water three times and dried over anhydrous Na2SO4, and the organic layer was directly chromatographed on a silica gel column eluting with toluene to give some compound 2. Then, the eluent was changed to toluene/ethyl acetate (50:1) to remove uncharacterizable products. Then, the eluent was changed to toluene/ethyl acetate (10:1); the first red band was some byproducts. The second red band was eluted with CS₂/toluene/ethyl acetate (1:2:4) to afford fullerenol 13 (150 mg, 0.133 mmol, 80%). Characterization data for 13: ¹H NMR (500 MHz, $C_6D_4Cl_2/CS_2$) δ : 7.58 (s, 4H), 6.89 (s, 4H), 5.64 (s, br, 2H, OH), 3.59 (s, 2H), 3.41 (s, 2H), 2.45 (s, 2H), 2.12 (s, 6H), 1.53 (s, 2H), 1.40 (s, 2H), 1.15 (m, 8H), 0.68 (s, 6H). ESI-FT-ICR-HRMS-Positive: $C_{86}H_{41}N_2O_2$ (M + H)⁺ calculated 1133.3163, found 1133.3195. (^{13}C NMR spectrum for the 13 could not be obtained due to low solubility).

Preparation of Compound 14. To a solution of compound 11 (198 mg, 0.176 mmol) in 50 mL of dry benzene was added DIB (114 mg, 0.352 mmol). The resulting solution was stirred at 35 °C for 1 h. The organic layer was directly chromatographed on a silica gel column eluting with toluene/ethyl acetate (100:1). The first red band was collected as compound 14 (170 mg, 0.151 mmol, 86%). Characterization data for 14: ¹H NMR (500 MHz, CDCl₃) δ : 8.10 (s, 2H), 7.44 (s, 2H), 7.37 (s, 1H), 3.85 (s, 1H), 3.63-3.58 (m, 4H), 3.27 (s, 1H), 2.86-2.73 (m, 3H), 2.53-2.51 (d, 2H, J = 9.9 Hz), 2.42 (m, 1H), 1.80-1.72 (m, 5H), 1.55-1.28 (m, 10H), 0.94 (s, 9H). ¹³C NMR (125 MHz, CDCl₃) (all signals represent 1C except noted) δ : 201.39, 199.90, 153.55, 152.29, 151.99, 151.80, 149.74, 149.63, 149.59, 149.53, 149.43, 149.32, 149.31, 149.27, 149.16, 148.81, 148.80, 148.71 (2C), 148.68, 148.62, 148.52, 148.21, 148.20, 148.13, 147.63, 147.62, 147.38, 146.95, 146.78, 145.27, 145.13, 145.12, 145.11, 144.92, 144.66, 144.60, 144.54, 144.51, 143.71, 143.63, 143.36, 142.98, 142.75, 142.72, 142.68, 142.44, 141.84, 141.81, 141.61, 141.36, 140.93, 140.76, 140.41, 139.16, 136.35, 134.90, 128.95 (2C), 128.56 (2C), 128.18, 82.00, 81.65, 69.49, 56.85, 52.69, 52.57, 52.47, 52.23, 51.52, 50.27, 35.29, 35.28, 35.23, 35.17, 35.15, 35.03, 30.82, 30.56, 30.47, 22.04, 22.00 (2C). FT-IR (microscope): 3059, 3026, 2949, 2921, 2871, 2842, 2810, 2757, 2703, 1744, 1720, 1598, 1495, 1461, 1445, 1377, 1320, 1279, 1258, 1235, 1205, 1160, 1105, 1076, 1032, 975, 940, 907, 845, 734, 698, 649 cm⁻¹. ESI-FT-ICR-HRMS-Positive: C₈₄H₄₂N₃O₂ (M + H)⁺ calculated 1124.3272, found 1124.3231.

Preparation of Compound 15. To a solution of compound 12 (124 mg, 0.11 mmol) in 50 mL of dry benzene and 5 mL of CS₂ was added DIB (71 mg, 0.22 mmol). The resulting solution was stirred at 35 °C for 1 h. The organic layer was directly chromatographed on a silica gel column eluting with toluene/ethyl acetate (100:1). The first red band was collected as compound 15 (110 mg, 0.098 mmol, 89%). Characterization data for 15: 1 H NMR (400 MHz, CDCl₃) δ : 8.09 (d,

2H, I = 7.5 Hz), 7.44 (dd, 2H, I1 = 7.3 Hz, I2 = 7.3 Hz), 7.34 (t, 1H, I= 7.1 Hz), 3.82 (d, 1H, I = 10.5 Hz), 3.69-3.54 (m, 4H), 3.22 (d, 1H, J = 9.9 Hz), 2.92–2.87 (m, 1H), 2.80–2.54 (m, 4H), 2.20–2.15 (m, 1H), 1.84–1.67 (m, 5H), 1.50–1.30 (m, 8H), 1.33–1.11 (m, 2H), 0.99 (d, 6H, I = 3.2 Hz), 0.90 (d, 3H, I = 5.9 Hz). ¹³C NMR (125 MHz, CDCl₃) (all signals represent 1C except noted) δ : 202.05, 199.46, 153.96, 152.86, 152.00, 150.47, 149.73, 149.45, 149.44, 149.30, 149.24, 149.05, 148.95 (2C), 148.82, 148.79, 148.65, 148.58, 148.51, 148.42, 148.39, 148.32, 148.05, 147.90, 147.47, 147.45, 147.28, 146.76, 146.61, 144.87, 144.75, 144.64, 144.58, 144.49, 144.23, 144.00, 143.95, 143.76, 143.62, 143.49, 143.31, 143.29, 142.98, 142.87, 142.67, 142.60, 142.57, 142.55, 141.71, 141.03, 141.01, 140.82, 140.64, 140.14, 138.42, 138.13, 134.95, 128.95 (2C), 128.59 (2C), 127.92, 81.80, 69.60, 69.36, 66.39, 52.57, 52.45, 51.75, 50.54, 50.45, 49.92, 35.19, 35.15, 35.09 (2C), 34.94 (2C), 30.77, 30.70, 30.42, 21.89 (2C), 21.80. FT-IR (microscope): 2948, 2921, 2870, 2841, 2809, 1744, 1720, 1495, 1460, 1443, 1377, 1320, 1279, 1257, 1205, 1159, 1106, 1079, 1032, 974, 907, 885, 773, 695, 649 cm⁻¹. ESI-FT-ICR-HRMS-Positive: C₈₄H₄₂N₃O₂ (M + H)+ calculated 1124.3272, found 1124.3264.

Preparation of Compound 16. To a solution of compound 13 (150 mg, 0.133 mmol) in 50 mL of dry benzene was added DIB (85 mg, 0.27 mmol). The resulting solution was stirred at 35 °C for 45 min. The organic layer was directly chromatographed on a silica gel column eluting with toluene. The first red band was collected as compound 16 (125 mg, 0.111 mmol, 83%). Characterization data for **16**: ¹H NMR (500 MHz, CDCl₃/CS₂) δ : 7.57 (d, 4H, J = 8 Hz), 7.05 (d, 4H, I = 7.9 Hz), 3.53 (d, 4H, I = 10.6 Hz), 2.73-2.69 (m, 2H),2.46-2.41 (m, 2H), 2.34 (s, 6H), 1.72 (d, 2H, J = 12.5 Hz), 1.66 (d, 2H, J = 12.6 Hz), 1.40-1.38 (m, 2H), 1.30-1.28 (m, 4H), 0.94 (s, 3H), 0.93 (s, 3H). ¹³C NMR (125 MHz, CDCl₃/CS₂) δ : 152.46, 152.02, 151.34, 149.58, 149.52, 149.37, 149.23, 148.76, 148.71, 148.59, 148.49, 148.18, 147.63, 147.25, 146.99, 145.29, 145.00, 144.82, 144.80, 144.54, 143.41, 142.99, 142.63, 142.60, 141.76, 141.44, 140.85, 137.70, 136.21, 135.47, 129.65 (4C), 128.26 (4C), 81.86 (2C), 56.37 (2C), 52.47 (2C), 52.16 (2C), 35.31 (2C), 35.17 (2C), 30.68 (2C), 22.12 (2C), 21.32 (2C). ¹H NMR (500 MHz, $C_6D_4Cl_2$) δ : 7.89 (d, 3H, J =6.4 Hz), 7.35-7.34 (m, 5H), 4.03 (d, 2H, J = 11.0 Hz), 3.80 (d, 2H, J = 10.4 Hz), 2.96 (t, 2H, J = 10.5 Hz), 2.82(t, 2H, J = 10.6 Hz), 2.44– 2.41 (m, 6H), 1.88–1.86 (m, 4H), 1.61–1.59 (m, 6H), 1.09 (s, 6H). ^{13}C NMR (125 MHz, $\text{C}_6\text{D}_4\text{Cl}_2)$ (some signals were hidden in solvent signals) δ : 197.78, 197.73, 151.37, 150.98, 149.82, 148.16, 147.99, 147.39, 147.34, 147.17, 147.14, 146.80, 146.31, 145.62, 143.99, 143.78, 143.70, 143.50, 143.21, 142.18, 141.55, 141.21, 141.19, 140.33, 140.11, 139.45, 136.59, 134.82, 134.40, 80.77, 55.45, 51.33 (2C), 50.78 (2C), 34.09 (2C), 34.00 (2C), 29.38 (2C), 20.62 (2C), 19.78 (2C)). FT-IR (microscope): 2950, 2923, 2852, 1743, 1511, 1463, 1261, 1107, 1072, 1022, 975, 810, 756 cm⁻¹. ESI-FT-ICR-HRMS-Positive: C₈₆H₃₉N₂O₂ (M + H)⁺ calculated 1131.3006, found 1131.3012.

Preparation of Compound 17. To a solution of compound 3 (124 mg, 0.112 mmol) in 80 mL of CH₂Cl₂ were added PPh₃ (253 mg, 0.448 mmol) and I₂ (455 mg, 1.79 mmol), and the resulting solution was stirred at room temperature for 1 day. Then, the reaction was treated with excess aqueous $\mathrm{Na_2S_2O_3}$ (100 mL) twice. The organic layer was washed further with aqueous NH₄Cl (100 mL) twice and dried over anhydrous Na2SO4, and the solvent was removed under vacuum. The residue was chromatographed on silica gel eluting with CS₂. A trace amount of the impurities was eluted out first. Then, the eluent was changed to toluene/CS₂ (1:1). The first band was collected and evaporated to give compound 17 (74 mg, 0.083 mmol, 74%, based on recovered starting material 88%) as a black solid. The eluting solvent was changed to toluene to give unreacted compound 3 (20 mg, 0.018 mmol) as an orange solid. Characterization data for 17: ¹H NMR (400 MHz, CDCl₃/CS₂) δ : 8.42 (d, 2H, J = 7.4 Hz), 7.60 (dd, 2H, J1 = 7.6 Hz, J2 = 7.6 Hz), 7.47 (t, 1H, J = 7.4 Hz), 4.07 (dd, 2H, J1 = 10.3 Hz, J2 = 22.9 Hz), 3.14-3.06 (m, 2H), 1.89 (s, br, 2H), 1.60-1.52 (m, 3H), 1.08 (d, 3H, J = 5.2 Hz). ¹³C NMR (125 MHz, $CDCl_3/CS_2$) (all signals represent 1C except noted) δ : 155.30, 153.05, 152.44, 149.74, 148.95, 148.69 (2C), 148.45, 147.78, 147.31, 147.25 (2C), 147.17 (3C), 147.15, 146.90, 146.80, 145.79, 145.72, 145.61, 145.55, 145.28, 144.79, 144.67, 144.63, 144.46, 144.42, 144.39 (2C),

144.25, 144.23, 144.13, 144.02, 143.92, 143.79, 143.64, 143.53, 143.49, 143.40, 143.37, 143.36, 143.29, 143.02 (2C), 142.94, 142.87, 142.68, 142.68, 142.60, 142.50, 142.29, 141.11, 140.93, 140.85, 140.17, 139.17, 138.28, 138.19, 129.42 (2C), 128.44 (2C), 128.29, 74.49, 62.02, 50.69, 49.77, 35.50, 35.44, 31.48, 22.36. ESI-FT-ICR-HRMS-Positive: $C_{72}H_{18}N$ (M + H)⁺ calculated 896.1450, found 896.1434.

Reaction of 5 with PPh₃/l₂. To a solution of compound **5** (100 mg, 0.0898 mmol) in 60 mL of CHCl₃ were added PPh₃ (94 mg, 0.36 mmol) and I₂ (365 mg, 1.44 mmol), and the resulting solution was stirred at room temperature for 1 day. Then, the reaction was treated with excess aqueous $Na_2S_2O_3$ (100 mL) twice. The organic layer was washed further with aqueous NH_4Cl (100 mL) twice and dried over anhydrous Na_2SO_4 , and the solvent was removed under vacuum. The residue was chromatographed on silica gel eluting with CS_2 . The first band was collected and evaporated to give compound **2** (22 mg, 0.024 mmol, 27%, based on recovered starting material 64%) as a black solid. The eluting solvent was changed to toluene to give unreacted compound **5** (58 mg, 0.052 mmol) as an orange solid.

ASSOCIATED CONTENT

S Supporting Information

Selected spectroscopic data for all new compounds and crystallographic data for 4, including CIF file. This material is available free of charge via the Internet at http://pubs.acs.org.

AUTHOR INFORMATION

Corresponding Author

*E-mail: gan@pku.edu.cn (L.G.).

Notes

The authors declare no competing financial interest.

ACKNOWLEDGMENTS

Financial support is provided by NNSFC (Grants 21272013 and 21132007) and MOST (2011CB808401) and (2015CB856600).

REFERENCES

- (1) (a) Hirsch, A.; Brettreich, M. Fullerenes: Chemistry and Reactions; Wiley-VCH Verlag GmbH & Co. KGaA: Weinheim, Germany, 2005. (b) Thilgen, C.; Diederich, F. Chem. Rev. 2006, 106, 5049. (c) Matsuo, Y.; Nakamura, E. Chem. Rev. 2008, 108, 3016.
- (2) For examples of C_s - $C_{60}X_6$: (a) Birkett, P. R.; Hitchcock, P. B.; Kroto, H. W.; Taylor, R.; Walton, D. R. M. Nature 1992, 357, 479. (b) Birkett, P. R.; Avent, A. G.; Darwish, A. D.; Kroto, H. W.; Taylor, R.; Walton, D. R. M. J. Chem. Soc., Chem. Commun. 1993, 1230. (c) Al-Matar, H.; Abdul-Sada, A. K.; Avent, A. G.; Fowler, P. W.; Hitchcock, P. B.; Rogers, K. M.; Taylor, R. J. Chem. Soc., Perkin Trans. 2 2002, 53. (d) Huang, S. H.; Xiao, Z.; Wang, F. D.; Gan, L. B.; Zhang, X.; Hu, X. Q.; Zhang, S. W.; Lu, M. J.; Pan, Q. Q.; Xu, L. J. Org. Chem. 2004, 69, 2442. (e) Troyanov, S. I.; Kemnitz, E. Eur. J. Org. Chem. 2005, 4951. (f) Kuvychko, I. V.; Streletskii, A. V.; Popov, A. A.; Kotsiris, S. G.; Drewello, T.; Strauss, S. H.; Boltalina, O. V. Chem.—Eur. J. 2005, 11, 5426. For examples of C_s-C₆₀YX₅: (g) Avent, A. G.; Birkett, P. R.; Crane, J. D.; Darwish, A. D.; Langley, G. J.; Kroto, H. W.; Taylor, R.; Walton, D. R. M. J. Chem. Soc., Chem. Commun. 1994, 1463. (h) Sawamura, M.; Iikura, H.; Nakamura, E. J. Am. Chem. Soc. 1996, 118, 12850. (i) Khakina, E. A.; Yurkova, A. A.; Peregudov, A. S.; Troyanov, S. I.; Trush, V. V.; Vovk, A. I.; Mumyatov, A. V.; Martynenko, V. M.; Balzarinie, J.; Troshin, P. A. Chem. Commun. 2012, 48, 7158,
- (3) Schick, G.; Kampe, K.-D.; Hirsch, A. J. Chem. Soc., Chem. Commun. 1995, 2023.
- (4) (a) Isobe, H.; Ohbayashi, A.; Sawamura, M.; Nakamura, E. *J. Am. Chem. Soc.* **2000**, *122*, 2669. (b) Isobe, H.; Tomita, N.; Nakamura, E. *Org. Lett.* **2000**, *2*, 3663. (c) Isobe, H.; Tanaka, T.; Nakanishi, W.; Lemiègre, L.; Nakamura, E. *J. Org. Chem.* **2005**, *70*, 4826. (d) Lemiègre, L.; Tanaka, T.; Nanao, T.; Isobe, H.; Nakamura, E. *Chem. Lett.* **2007**,

- 36, 20. (e) Troshina, O. A.; Troshin, P. A.; Peregudov, A. S.; Kozlovski, V. I.; Lyubovskaya, R. N. *Chem.—Eur. J.* **2006**, 12, 5569. (f) Zhang, X.; Gan, L. B.; Huang, S. H.; Shi, Y. R. *J. Org. Chem.* **2004**, 69, 5800.
- (5) Gan, L. B.; Huang, S. H.; Zhang, X.; Zhang, A. X.; Cheng, B. C.; Cheng, H.; Li, X. L.; Shang, G. J. Am. Chem. Soc. 2002, 124, 13384.
- (6) (a) Avent, A. G.; Birkett, P. R.; Crane, J. D.; Darwish, A. D.; Langley, G. J.; Kroto, H. W.; Taylor, R.; Walton, D. R. M. J. Chem. Soc., Chem. Commun. 1994, 1463. (b) Kennedy, R. D.; Halim, M.; Khan, S. I.; Schwartz, B. J.; Tolbert, S. H.; Rubin, Y. Chem.—Eur. J. 2012, 18, 7418
- (7) Clavaguera, S.; Khan, S. I.; Rubin, Y. Org. Lett. 2009, 6, 1389.
- (8) Kareev, I. E.; Shustova, N. B.; Kuvychko, I. V.; Lebedkin, S. F.; Miller, S. M.; Anderson, O. P.; Popov, A. A.; Strauss, S. H.; Boltalina, O. V. J. Am. Chem. Soc. **2006**, 128, 12268.
- (9) For example: (a) Maeda-Mamiya, R.; Noiri, E.; Isobe, H.; Nakanishi, W.; Okamoto, K.; Doi, K.; Sugayad, T.; Izumi, T.; Homma, T.; Nakamura, E. *Proc. Natl. Acad. Sci. U.S.A.* **2010**, *107*, 5339. (b) Nakamura, E.; Isobe, H. *Chem. Rec.* **2010**, *10*, 260. (c) Kornev, A. B.; Khakina, E. A.; Troyanov, S. I.; Kushch, A. A.; Peregudov, A.; Vasilchenko, A.; Deryabin, D. G.; Martynenko, V. M.; Troshin, P. A. *Chem. Commun.* **2012**, *48*, 5461. (d) Troshina, O. A.; Troshin, P. A.; Peregudov, A. S.; Kozlovskiy, V. I.; Balzarini, J.; Lyubovskaya, R. N. *Org. Biomol. Chem.* **2007**, *5*, 2783.
- (10) Gan, L. B. Chem. Rec. 2015, 15, 189.
- (11) Huang, S. H.; Yang, X. B.; Zhang, X.; Hu, X. Q.; Gan, L. B.; Zhang, S. W. Synlett 2006, 1266.
- (12) For a recent example: Xu, L.; Liang, S. S.; Gan, L. B. Org. Chem. Front. 2014, 1, 652.
- (13) Huang, H.; Zhang, G. H.; Wang, D.; Xin, N. N.; Liang, S. S.; Wang, N. D.; Gan, L. B. Angew. Chem., Int. Ed. 2013, 52, 5037.
- (14) Wang, G. W.; Lu, Y. M.; Chen, Z. X. Org. Lett. 2009, 11, 1507. (15) (a) Nambo, M.; Segawa, Y.; Itami, K. J. Am. Chem. Soc. 2011, 133, 2402. (b) Tajima, Y.; Hara, T.; Honma, T.; Matsumoto, S.; Takeuchi, K. Org. Lett. 2006, 8, 3203. (c) Li, Y. B.; Lou, N.; Gan, L. B. Org. Lett. 2015, 17, 524.
- (16) Troshida, O. A.; Troshin, P. A.; Peregudov, A. S.; Lyubovskaya, R. N. Org. Biomol. Chem. **2006**, *4*, 1647.
- (17) Liang, S. S.; Xu, L.; Jia, Z. S.; Gan, L. B. J. Org. Chem. 2014, 79, 5794.
- (18) Huang, S. H.; Wang, F. D.; Gan, L. B.; Yuan, G.; Zhou, J.; Zhang, S. W. Org. Lett. 2006, 8, 277.
- (19) For a discussion on a possible mechanism of formation of the two isomers **10a** and **10b**, see the Supporting Information on page S2. (20) Balch, A. L.; Costa, D. A.; Lee, J. W.; Noll, B. C.; Olmstead, M.
- M. Inorg. Chem. 1994, 33, 2071. (21) Analogous 1,4-aminobenzyl C_{60} adducts have been reported: Si, W. L.; Lu, S. R.; Bao, M.; Asao, N.; Yamamoto, Y.; Jin, T. N. Org. Lett. 2014, 16, 620.